Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial

By sjmartinez • August 22, 2022

Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, Yang T, Basehart V, Reiter RE, Saigal C, Chamie K, Litwin MS, Rettig MB, Nickols NG, Yoon SM, Smith L, Gao Y, Steinberg ML, Cao M, Kishan AU. Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022 Aug 22:S0360-3016(22)03160-1. doi: 10.1016/j.ijrobp.2022.08.041. Epub ahead of print. PMID: 36007724.

MRI-guided radiotherapy, Prostate cancer, Stereotactic Body Radiation Therapy, postprostatectomy radiation, quality of life, radical prostatectomy,

Tags: Hematology/Oncology, MRI-guided radiotherapy, postprostatectomy radiation, prostate cancer, Publications, Quality of Life, radical prostatectomy, Stereotactic Body Radiation Therapy

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States

Balogh EP, Levit LA, Unger JM, Accordino MK, Chism DD, Kirkwood MK, Parsons HM, Patel MI, Peppercorn JM, Polite BN, Sedrak MS, Sharma P, Subbiah[...]

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P,[...]